Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts.
about
Updates of mTOR inhibitorsNext-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategymTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors.Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and PerspectivesDeciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?Prioritizing therapeutic targets using patient-derived xenograft modelsGenotype directed therapy in murine mismatch repair deficient tumorsSpecific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cellsMolecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts.A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid MalignanciesThe efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.NVP-BEZ-235 enhances radiosensitization via blockade of the PI3K/mTOR pathway in cisplatin-resistant non-small cell lung carcinomaMET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.Glial progenitors as targets for transformation in glioma.Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.Tumor cells switch to mitochondrial oxidative phosphorylation under radiation via mTOR-mediated hexokinase II inhibition--a Warburg-reversing effectDual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas.Cell-to-cell variability in PI3K protein level regulates PI3K-AKT pathway activity in cell populations.Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models.Crocetinic acid inhibits hedgehog signaling to inhibit pancreatic cancer stem cells.PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models.Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma.Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLCmTOR pathway in colorectal cancer: an update.New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma.Current development of the second generation of mTOR inhibitors as anticancer agents.Current clinical development of PI3K pathway inhibitors in glioblastoma.Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma.
P2860
Q24607170-E0F6ADDB-FACF-442B-A8E1-186C8F00D982Q24628724-3C59CB02-C017-4C64-954C-8B5A92E85402Q27851707-972B8515-2411-43F4-8724-4F6447E3B776Q28071388-963010D8-F9F2-42A0-8106-C87DEC5B874DQ28079848-25D17617-FF53-4120-858D-E09A589F1338Q28083993-CCA90BC3-2C65-49BB-902F-B1C07B68BB6DQ28534803-F5FBEFF1-14D3-43E4-8B8C-4A98A42A87E5Q33564297-98B52246-CC73-474B-AC44-DEF531D3D243Q33644407-0D361E42-11FE-4C0A-B970-022412AA66D4Q33709656-B8259291-81D8-42A1-A2A2-AC4A2AC51926Q33735754-16CA0E7E-6D6C-40AF-8466-C88C6CCE778EQ34001234-ADC3EE3E-C757-4CA5-96BB-C34B84CBE776Q34038031-E635A0FF-F6A2-4F67-81A2-8770443E6CFBQ34170552-88ADA6DF-F17E-4D00-A0C1-93E92D76964BQ34182679-AD072AF5-31DF-4844-B95D-3248343C46ABQ34226670-1010BEE6-2CB1-4840-BCE7-3E406AC2B785Q34291001-CB3E2DE1-86DE-40CF-8916-5F0DBA4D4217Q34682072-61D812CF-401E-4DD6-9090-8175C2EAF88AQ34735661-543F09F0-3AC1-40D6-8984-372877D2DCDFQ35177682-DCA3D24F-7FFF-4B6C-98AF-221A755BCA88Q35217017-5BE39ED6-A96E-4BC6-9E25-FF6822BAD27CQ35839063-26B39E49-F32C-4061-9B2A-CE721BE7BA23Q35948581-8CBAE3B8-F583-4023-B598-DA8373EE497CQ35992132-B7A1E70B-FA99-496F-BAB2-19BAB014130DQ36088956-41F3B3BF-EDBC-4003-BC5C-2D59605C6C68Q36108187-65C87C16-9792-45F1-9988-9EBE05D31EBDQ36413867-9EF2F5B5-76AB-49E2-B154-329F541CB81AQ36718464-3459AB0B-F438-4346-9058-7735AAC8F278Q37016570-3652F865-F94C-4178-9D48-162B6E9F94F4Q37030911-3288C139-EB4D-4F96-A502-D249644C8AD8Q37091157-D2727538-924F-4EAE-82EF-7F7359EFF0DAQ37350230-7478BC46-A9E2-476F-93C0-AF6B030128BBQ37554263-01AC039C-0A8B-444A-80BA-07C9BAE6D4FEQ37645002-9D9855EF-7930-49A1-A6E1-6C47B284B4CDQ37649634-E4B672EF-B06C-4834-B899-88A81EE0FC47Q37766888-9CC55A12-DC58-4477-89AB-2B8AF356FACCQ37856382-D48F0CA2-6060-4C6C-A077-6DA9ED74BC07Q37953476-48DCDF69-3122-415A-B324-7A0BF1F95ED1Q38012438-E3A89FE2-7FE4-408F-BFF4-4FE925EF91A9Q38111449-C426832C-FBED-47DD-A3BA-1CBD7BB6BE5C
P2860
Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Activity of a novel, dual PI3- ...... rown as orthotopic xenografts.
@en
Activity of a novel, dual PI3- ...... rown as orthotopic xenografts.
@nl
type
label
Activity of a novel, dual PI3- ...... rown as orthotopic xenografts.
@en
Activity of a novel, dual PI3- ...... rown as orthotopic xenografts.
@nl
prefLabel
Activity of a novel, dual PI3- ...... rown as orthotopic xenografts.
@en
Activity of a novel, dual PI3- ...... rown as orthotopic xenografts.
@nl
P2093
P2860
P356
P1476
Activity of a novel, dual PI3- ...... grown as orthotopic xenografts
@en
P2093
C García-Echeverría
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604995
P407
P50
P577
2009-03-24T00:00:00Z